Rankings
▼
Calendar
ANIP Q4 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ANIP
ANI Pharmaceuticals, Inc.
$2B
Q4 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$132M
+39.7% YoY
Gross Profit
$78M
59.4% margin
Operating Income
$7M
5.1% margin
Net Income
$1M
0.9% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
-0.1%
Cash Flow
Operating Cash Flow
$45M
Free Cash Flow
$40M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$904M
Total Liabilities
$447M
Stockholders' Equity
$458M
Cash & Equivalents
$221M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$132M
$94M
+39.7%
Gross Profit
$78M
$58M
+35.1%
Operating Income
$7M
$2M
+269.6%
Net Income
$1M
-$4M
+127.2%
Revenue Segments
Rare Disease
$199M
64%
Sales of rare disease pharmaceutical products
$112M
36%
Geographic Segments
United States
$132M
100%
← FY 2023
All Quarters
Q1 2024 →